Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 5
1984 8
1985 15
1986 13
1987 24
1988 16
1989 46
1990 28
1991 42
1992 60
1993 46
1994 100
1995 168
1996 150
1997 142
1998 184
1999 203
2000 176
2001 166
2002 149
2003 182
2004 154
2005 182
2006 137
2007 119
2008 91
2009 88
2010 105
2011 108
2012 95
2013 89
2014 82
2015 103
2016 72
2017 72
2018 84
2019 63
2020 52
2021 34
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

3,495 results
Results by year
Filters applied: . Clear all
Page 1
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.
Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, Ang Y, Morris D, Bhandari P, Brooks C, Attwood S, Harrison R, Barr H, Moayyedi P; AspECT Trial Team. Jankowski JAZ, et al. Lancet. 2018 Aug 4;392(10145):400-408. doi: 10.1016/S0140-6736(18)31388-6. Epub 2018 Jul 26. Lancet. 2018. PMID: 30057104 Free PMC article. Clinical Trial.
BACKGROUND: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett's oesophagus is the biggest risk factor. We aimed to evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and aspirin for improving outcomes i …
BACKGROUND: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett's oesophagus is the biggest risk …
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG; Esomeprazole Study Investigators. Richter JE, et al. Am J Gastroenterol. 2001 Mar;96(3):656-65. doi: 10.1111/j.1572-0241.2001.3600_b.x. Am J Gastroenterol. 2001. PMID: 11280530 Clinical Trial.
Healing rates at wk 4 were 81.7% and 68.7%, respectively. Esomeprazole was superior to omeprazole for all secondary measures and had a similar safety profile. ...The tolerability and safety of esomeprazole are comparable to that of omeprazole. (Am...
Healing rates at wk 4 were 81.7% and 68.7%, respectively. Esomeprazole was superior to omeprazole for all secondary measures a …
Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH, Wu DC, Hsu PI, Kuo CH, Tai WC, Yang SC, Wu KL, Yao CC, Tsai CE, Liang CM, Wang YK, Wang JW, Huang CF, Chuah SK; Taiwan Acid-Related Disease Study Group. Chiang HH, et al. Drug Des Devel Ther. 2019 Apr 26;13:1347-1356. doi: 10.2147/DDDT.S193559. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31118571 Free PMC article. Clinical Trial.
Purpose: Research comparing the clinical efficacy of dexlansoprazole and esomeprazole has been limited. This study aims to compare the clinical efficacy of single doses of dexlansoprazole (modified-release 60 mg) and esomeprazole (40 mg) after 24-week follow-up in p …
Purpose: Research comparing the clinical efficacy of dexlansoprazole and esomeprazole has been limited. This study aims to compare th …
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P Jr, Katz PO, Chen Y, Sostek M. Miner P Jr, et al. Am J Gastroenterol. 2003 Dec;98(12):2616-20. doi: 10.1111/j.1572-0241.2003.08783.x. Am J Gastroenterol. 2003. PMID: 14687806 Clinical Trial.
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. ...On day 5, intragastric pH was maintained above 4.0 for a mean of 14.0 h with esomeprazole …
The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, om …
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Yeomans ND, Graham DY, Husni ME, Solomon DH, Stevens T, Vargo J, Wang Q, Wisniewski LM, Wolski KE, Borer JS, Libby P, Lincoff AM, Lüscher TF, Bao W, Walker C, Nissen SE; PRECISION investigators. Yeomans ND, et al. Aliment Pharmacol Ther. 2018 Jun;47(11):1453-1463. doi: 10.1111/apt.14610. Epub 2018 Apr 17. Aliment Pharmacol Ther. 2018. PMID: 29667211 Clinical Trial.
., ibuprofen 600-800 mg t.d.s. or naproxen 375-500 mg b.d. plus esomeprazole, and low-dose aspirin or corticosteroids if already prescribed. ...Co-prescribed with esomeprazole, celecoxib has better overall GI safety than ibuprofen or naproxen at these doses, despite …
., ibuprofen 600-800 mg t.d.s. or naproxen 375-500 mg b.d. plus esomeprazole, and low-dose aspirin or corticosteroids if already pres …
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL 3rd, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD. Frelinger AL 3rd, et al. J Am Coll Cardiol. 2012 Apr 3;59(14):1304-11. doi: 10.1016/j.jacc.2011.12.024. J Am Coll Cardiol. 2012. PMID: 22464259 Free article. Clinical Trial.
Clopidogrel 75 mg with or without a PPI (dexlansoprazole 60 mg, lansoprazole 30 mg, esomeprazole 40 mg, or, as a positive control to maximize potential interaction and demonstrate assay sensitivity, omeprazole 80 mg) was given daily for 9 days. ...CONCLUSIONS: Gener …
Clopidogrel 75 mg with or without a PPI (dexlansoprazole 60 mg, lansoprazole 30 mg, esomeprazole 40 mg, or, as a positive control to …
Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Sakurai K, Suda H, Fujie S, Takeichi T, Okuda A, Murao T, Hasuda K, Hirano M, Ito K, Tsuruta K, Hattori M. Sakurai K, et al. Dig Dis Sci. 2019 Mar;64(3):815-822. doi: 10.1007/s10620-018-5365-0. Epub 2018 Nov 10. Dig Dis Sci. 2019. PMID: 30415407 Free PMC article. Clinical Trial.
However, few reports have investigated the onset of action of these agents for GERD symptom relief. The present study compared the symptom relief of esomeprazole with that of vonoprazan via monitoring self-reported GERD symptoms after treatment initiation. METHODS: This wa …
However, few reports have investigated the onset of action of these agents for GERD symptom relief. The present study compared the symptom r …
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Çelebi A, et al. Turk J Gastroenterol. 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514. Turk J Gastroenterol. 2016. PMID: 27782887 Free article. Clinical Trial.
Efficacy analysis on days 1 and 5 were performed on the four groups which comprised 10 (esomeprazole), 11 (rabeprazole), 10 (lansoprazole), and 10 (pantoprazole) patients. ...When the time needed to raise the intragatric pH to over 4 was evaluated, esomeprazole was …
Efficacy analysis on days 1 and 5 were performed on the four groups which comprised 10 (esomeprazole), 11 (rabeprazole), 10 (lansopra …
Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial.
Sun QH, Wang HY, Sun SD, Zhang X, Zhang H. Sun QH, et al. World J Gastroenterol. 2019 May 7;25(17):2110-2121. doi: 10.3748/wjg.v25.i17.2110. World J Gastroenterol. 2019. PMID: 31114137 Free PMC article. Clinical Trial.
AIM: To evaluate the therapeutic effects in RE patients treated with a combination of esomeprazole and probiotics [Bacillus subtilis (B. subtilis) and Enterococcus faecium (E. faecium)]. METHODS: One hundred and thirty-four RE patients were randomized into two groups of 67 …
AIM: To evaluate the therapeutic effects in RE patients treated with a combination of esomeprazole and probiotics [Bacillus subtilis …
3,495 results